necitumumab

Known as: Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor (Receptor Tyrosine-Protein Kinase ErbB-1, EC 2.7.10.1)); Human Monoclonal IMC-11F8 Gamma1 Heavy Chain (224-214')-Disulfide with Human Monoclonal IMC-11F8 Kappa Light Chain, Dimer (230- 230'':233-233'')-Bisdisulfide 
A fully human IgG1 monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2018
05101520102018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Necitumumab is a second-generation, recombinant, human immunoglobulin G1, epidermal growth factor (EGFR) receptor antibody that… (More)
  • table 1
  • figure 2
  • figure 1
  • table 2
  • table 3
Is this relevant?
2016
2016
BACKGROUND SQUIRE demonstrated addition of necitumumab to gemcitabine and cisplatin significantly improved survival in patients… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
2016
2016
Background:This single-arm phase II study investigated the EGFR monoclonal antibody necitumumab plus modified FOLFOX6 (mFOLFOX6… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Review
2016
Review
2016
Eli Lilly is developing necitumumab (Portrazza™), an intravenously administered fully human IgG monoclonal antibody directed… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Necitumumab is a second-generation, recombinant, human immunoglobulin G1 EGFR antibody. In this study, we aimed to… (More)
  • table 1
  • figure 2
  • table 3
Is this relevant?
2015
2015
BACKGROUND Necitumumab is a second-generation recombinant human immunoglobulin G1 EGFR monoclonal antibody that competitively… (More)
Is this relevant?
2015
2015
IMPORTANCE The SQUIRE trial demonstrated that adding necitumumab to chemotherapy for patients with metastatic squamous cell lung… (More)
Is this relevant?
2011
2011
e21075 Background: Necitumumab, cetuximab and panitumumab are monoclonal antibodies specific for human epidermal growth factor… (More)
Is this relevant?
2011
2011
e13030 Background: The monoclonal antibodies cetuximab (chimeric IgG1), necitumumab (human IgG1), and panitumumab (human IgG2… (More)
Is this relevant?
2010
2010
PURPOSE This study aimed to determine a maximum tolerated dose (MTD) and recommended dose for disease-directed studies of… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?